Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Immunitum
- Development stage
- Phase 2
- Lead developer
- Actigenomics
- Administration
- Oral
01
Overview
**Immunitum** is an orally administered dietary supplement developed by Actigenomics and positioned to support immune status and reduce the frequency, duration, and intensity of infectious episodes. It was evaluated in a randomized, double-blind, placebo-controlled study in Rwanda among children aged 12–59 months with moderate malnutrition, including assessment of recurrent upper respiratory, bronchopulmonary, gastrointestinal, and malaria-related infectious episodes. Its specific active composition, molecular targets, and mechanism of action have not been publicly disclosed in the identified sources. ([epistemonikos.org](https://www.epistemonikos.org/en/documents/ba892fdff39370de41f7c62b5773bc12791e0fa8))
- Brand names
- Immunitum
02
Targets
RAR (Retinoic acid receptor)RXRA (Retinoid X receptor alpha)VDR (Vitamin D receptor)
Beyond the preview
Go deeper on Immunitum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunitum.